Search companies

Live

ACTINOGEN MEDICAL LIMITED (ASX: ACW)

Health care · News and insights

Price unavailable

Latest ACW announcements

Announcement Insights

Actinogen Delays XanaMIA Results as It Analyses Additional Trial Data

Actinogen Medical’s expected mid-November topline results from its XanaMIA Alzheimer’s trial remain pending as the company analyses additional data, with its shares moving from a trading halt on November 13 to a voluntary suspension on November 17. The trial had reached database lock by October, but the company said further analysis was needed before releasing results.

Updated 17 Nov 2026, 10:43 AM Sydney time
Share
SourcesSuspension from QuotationTrading HaltRequest for Trading HaltUpdate - Notification of buy-back - ACWNotification of cessation of securities - ACWResponse to ASX Price QueryLetter to Shareholders, Notice of AGM & Proxy Form
Comments

Actinogen Suspended As It Analyses XanaMIA Alzheimer’s Trial Data

2026-11-17 · Health care

Actinogen Medical has requested a voluntary suspension while it completes further analysis of additional data received for its XanaMIA phase 2b/3 Alzheimer’s trial, ahead of releasing topline results. The suspension is requested to remain in place until the results announcement or the start of trading on Thursday.

Updated 2026-11-17 10:35
Share
SourcesSuspension from Quotation
Comments

Actinogen Says No Unannounced Information Behind Trading, Points to Mid-November Trial Results

2026-11-09 · Health care

ACW: $0.048 +17.07% · MC: $182M

Actinogen Medical told the ASX it knows of no unannounced information that could explain recent trading in its shares. It pointed to its October update that the XanaMIA Alzheimer’s trial had reached database lock, with topline results expected in mid-November 2026.

Updated 2026-11-09 16:37
Share
SourcesResponse to ASX Price Query
Comments